| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e53ddadc8822457d5979471ddd1d8ab8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 |
| filingDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfdbed2904929ce8bfda1306b659c900
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_554908a06d0f44f0a4c4669f97e002b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13576be5839b38bd5c836c414cf3a0bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8395f597c0a491be43734a101a59229d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c0b51e04931739452a57c6b2bb61c8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98b2e2cf0a2ac168c7eb8cf2c356386d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab28436b85ddc8299a38bd1355a34a9 |
| publicationDate |
2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021221359-A1 |
| titleOfInvention |
Long-acting glp-1 and glucagon receptor dual agonist |
| abstract |
The present invention relates to a novel long-acting acylated oxyntomodulin peptide analogue having dual activation efficacy (dual GLP-1R/GlucagonR agonism) for glucagon-like peptide-1 (GLP-1) and a glucagon receptor, and to a pharmaceutical composition comprising same, for the prevention and treatment of obesity and being overweight, or non-insulin-dependent diabetes accompanied by obesity and being overweight. The acylated oxyntomodulin peptide analogue of the present invention includes dual activation efficacy for GLP-1/glucagon receptor and has an excellent increased in vivo half-life, and the pharmaceutical composition comprising same is useful for the treatment of metabolic diseases such as obesity and diabetes. |
| priorityDate |
2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |